Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide for cardiac surgery-associated acute kidney injury (CS-AKI). This marks the second Canadian site activation after University of Calgary Hospital and precedes the anticipated activation of St. Michael’s Hospital in Toronto. The company aims to recruit roughly half of the trial’s 240 patients in North America, supplementing ongoing enrollment in Turkey.
This expansion into prominent North American research centers reflects growing confidence in LSALT’s safety profile, established through earlier patient dosing in Turkey. While Arch maintains its global recruitment strategy for data diversity, the focus on North American sites likely reflects a dual objective: accelerating enrollment velocity and generating data relevant to key regulatory and commercial stakeholders in these markets. The company is actively seeking additional sites in both Canada and the US.
The move also highlights the operational challenges inherent in multinational trials. While Turkish enrollment appears to be progressing smoothly, Canadian sites require a 12-18 month lead time for regulatory and ethics approvals. This underscores the need for sponsors to build flexibility into their timelines and resource allocation, particularly when navigating diverse regulatory landscapes. Arch has adjusted the estimated trial completion date to August 2026 on ClinicalTrials.gov to reflect these timelines.
The Phase 2 trial design—randomized, double-blind, and placebo-controlled—reflects a conventional approach aimed at generating robust evidence for LSALT’s efficacy in preventing CS-AKI as defined by KDIGO criteria. The trial is primarily funded through non-dilutive grants, a strategic decision mitigating financial risk while validating scientific merit to potential investors and partners.
Looking ahead, Arch faces several critical junctures. Reproducing the positive biomarker signals observed in the earlier acute lung inflammation trial will be key to supporting LSALT’s mechanism of action in the kidney. The company must also demonstrate a clear clinical benefit in CS-AKI prevention, a high-unmet-need area where current preventative options are limited. The trial’s success will be crucial for attracting larger partners or securing funding for Phase 3 development, particularly given the competitive landscape for kidney disease therapeutics. Finally, Arch will need to address manufacturing scalability and commercialization strategies as it moves closer to potential market entry.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Innovation at the Intersection of Surgery, Inflammation, and AI in Clinical Trials
1 year ago[…] In parallel, Arch Biopartners has dosed the first patient in its Phase 2 trial evaluating LSALT peptide (Metablok) for inflammation-related complications. The peptide is being tested for its efficacy in reducing organ inflammation—particularly in the lungs and kidneys—during systemic inflammatory responses such as sepsis or COVID-19. LSALT targets dipeptidase-1 (DPEP-1), an enzyme linked to leukocyte migration into organs. By inhibiting this pathway, the peptide aims to mitigate tissue damage and reduce mortality associated with acute inflammatory conditions. This trial is not just a test of a new drug—it’s part of a broader move toward biomarker-driven, organ-specific inflammation therapies (source). […]